Imsidolimab

About AnaptysBio

AnaptysBio is a clinical-stage biotech advancing a pipeline of best-in-class antibodies designed to dampen inflammatory responses and restore immune balance in autoimmune and inflammatory diseases. The company has demonstrated its antibody discovery capabilities through out-licensed assets like Jemperli (GSK) and imsidolimab (Vanda Pharmaceuticals), which provide royalty revenue. Strategically, AnaptysBio has announced its intent to separate its biopharma operations from its royalty assets by year-end 2026, aiming to create two distinct investment vehicles focused on development and financial assets, respectively.

About Vanda Pharmaceuticals

Founded in 2003 and publicly traded on NASDAQ (VNDA), Vanda Pharmaceuticals leverages genetics and genomics to inform drug discovery and development. The company has achieved significant milestones with FDA approvals for Fanapt® (2009) and HETLIOZ® (2014), and continues to expand its pipeline with late-stage candidates like tradipitant and imsidolimab. Vanda's strategic focus combines commercial execution with a science-driven approach to address complex disorders in circadian rhythms, psychiatry, and inflammation.

Therapeutic Areas